TFF Pharmaceuticals announced that it has been working with Aptar Pharma on a project to develop dry powder vaccines based on TFF’s thin film freezing particle manufacturing platform and Aptar Pharma’s Unidose (UDS) nasal powder delivery device. According to the company, Aptar Pharma presented data from the project at the recent Vaccines Summit 2022 and will present more data at an upcoming vaccine meeting, with a submission to a peer-reviewed journal to follow.
In March 2022, TFF announced that it had entered into an agreement with the US Army and the Geneva Foundation for formulation of dry powder nasal vaccine against SARS-CoV-2. The company had previously announced a deal with the US Army for development of dry powder inhaled and/or nasal vaccines against alphaviruses and filoviruses.
TFF Pharmaceuticals President and CEO Glenn Mattes said, “We are very excited to partner with Aptar Pharma to test our thin film freezing formulation with their unique intranasal device. By combining our collective and proprietary expertise in drug development, device engineering and formulation technologies, we believe this collaboration has the potential to create ground-breaking advancements in the field of drug delivery. Intranasal dry powder vaccines could be a true game changer for people around the world.”
Aptar Pharma VP of Scientific Affairs Julie Suman commented, “The nasal vaccine formulation developed using TFF Pharmaceutical’s technology combines the antigen and adjuvant into one ready to use device. This eliminates the need for combining separate vials, saves time, reduces human error and medical waste.”
Read the TFF Pharmaceuticals press release.
